CD47 and anemia: Anemia, which has been frequently observed with other CD47 blockers, only occurred in 25% of patients in this trial and was low-grade in all cases except one (co-occurring with HLH), consistent with evorpacept’s inactive Fc domain and prior data (16, 61).